Castration Resistant Prostate Cancer Treatment Market Report

Global Castration Resistant Prostate Cancer Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：204
  • REPORT CODE：GMM860162
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Castration Resistant Prostate Cancer Treatment market report explains the definition, types, applications, major countries, and major players of the Castration Resistant Prostate Cancer Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Hologic

    • Spectrum Pharmaceuticals

    • Bayer Healthcare Pharmaceuticals

    • Glaxosmithkline

    • Abbott Laboratories

    • Diagnocure

    • Active Biotech

    • Millennium Pharmaceuticals

    • Northwest Biotherapeutics

    By Type:

    • Hormonal Therapy

    • Adding An Anti-Androgen

    • Stopping An Anti-Androgen

    • Estrogens

    • Chemotherapy

    • Radiation Therapy

    • Others

    By End-User:

    • Hospital

    • Ambulatory Surgical Centers

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Castration Resistant Prostate Cancer Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Castration Resistant Prostate Cancer Treatment Outlook to 2028- Original Forecasts

    • 2.2 Castration Resistant Prostate Cancer Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Castration Resistant Prostate Cancer Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Castration Resistant Prostate Cancer Treatment Market- Recent Developments

    • 6.1 Castration Resistant Prostate Cancer Treatment Market News and Developments

    • 6.2 Castration Resistant Prostate Cancer Treatment Market Deals Landscape

    7 Castration Resistant Prostate Cancer Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Castration Resistant Prostate Cancer Treatment Key Raw Materials

    • 7.2 Castration Resistant Prostate Cancer Treatment Price Trend of Key Raw Materials

    • 7.3 Castration Resistant Prostate Cancer Treatment Key Suppliers of Raw Materials

    • 7.4 Castration Resistant Prostate Cancer Treatment Market Concentration Rate of Raw Materials

    • 7.5 Castration Resistant Prostate Cancer Treatment Cost Structure Analysis

      • 7.5.1 Castration Resistant Prostate Cancer Treatment Raw Materials Analysis

      • 7.5.2 Castration Resistant Prostate Cancer Treatment Labor Cost Analysis

      • 7.5.3 Castration Resistant Prostate Cancer Treatment Manufacturing Expenses Analysis

    8 Global Castration Resistant Prostate Cancer Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Castration Resistant Prostate Cancer Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Castration Resistant Prostate Cancer Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Castration Resistant Prostate Cancer Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Hormonal Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Adding An Anti-Androgen Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Stopping An Anti-Androgen Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Estrogens Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Chemotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Radiation Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Castration Resistant Prostate Cancer Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.2.2 Canada Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.2 UK Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.3 Spain Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.5 France Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.6 Italy Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.8 Finland Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.9 Norway Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.11 Poland Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.12 Russia Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.2 Japan Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.3 India Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.5.3 Chile Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.5.6 Peru Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.6.3 Oman Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Castration Resistant Prostate Cancer Treatment Consumption (2017-2022)

    11 Global Castration Resistant Prostate Cancer Treatment Competitive Analysis

    • 11.1 Hologic

      • 11.1.1 Hologic Company Details

      • 11.1.2 Hologic Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Hologic Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.1.4 Hologic Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Spectrum Pharmaceuticals

      • 11.2.1 Spectrum Pharmaceuticals Company Details

      • 11.2.2 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.2.4 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Bayer Healthcare Pharmaceuticals

      • 11.3.1 Bayer Healthcare Pharmaceuticals Company Details

      • 11.3.2 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.3.4 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Glaxosmithkline

      • 11.4.1 Glaxosmithkline Company Details

      • 11.4.2 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.4.4 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Abbott Laboratories

      • 11.5.1 Abbott Laboratories Company Details

      • 11.5.2 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.5.4 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Diagnocure

      • 11.6.1 Diagnocure Company Details

      • 11.6.2 Diagnocure Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Diagnocure Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.6.4 Diagnocure Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Active Biotech

      • 11.7.1 Active Biotech Company Details

      • 11.7.2 Active Biotech Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Active Biotech Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.7.4 Active Biotech Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Millennium Pharmaceuticals

      • 11.8.1 Millennium Pharmaceuticals Company Details

      • 11.8.2 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.8.4 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Northwest Biotherapeutics

      • 11.9.1 Northwest Biotherapeutics Company Details

      • 11.9.2 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

      • 11.9.4 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    12 Global Castration Resistant Prostate Cancer Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Hormonal Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Adding An Anti-Androgen Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Stopping An Anti-Androgen Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Estrogens Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.6 Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.7 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Castration Resistant Prostate Cancer Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Castration Resistant Prostate Cancer Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Castration Resistant Prostate Cancer Treatment

    • Figure of Castration Resistant Prostate Cancer Treatment Picture

    • Table Global Castration Resistant Prostate Cancer Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Castration Resistant Prostate Cancer Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Hormonal Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Adding An Anti-Androgen Consumption and Growth Rate (2017-2022)

    • Figure Global Stopping An Anti-Androgen Consumption and Growth Rate (2017-2022)

    • Figure Global Estrogens Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Radiation Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Table North America Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Figure United States Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Figure Germany Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Figure China Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Figure Brazil Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Castration Resistant Prostate Cancer Treatment Consumption by Country (2017-2022)

    • Figure Australia Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Castration Resistant Prostate Cancer Treatment Consumption and Growth Rate (2017-2022)

    • Table Hologic Company Details

    • Table Hologic Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hologic Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Hologic Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Spectrum Pharmaceuticals Company Details

    • Table Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Bayer Healthcare Pharmaceuticals Company Details

    • Table Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Glaxosmithkline Company Details

    • Table Glaxosmithkline Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glaxosmithkline Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Glaxosmithkline Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Abbott Laboratories Company Details

    • Table Abbott Laboratories Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Laboratories Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Abbott Laboratories Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Diagnocure Company Details

    • Table Diagnocure Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Diagnocure Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Diagnocure Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Active Biotech Company Details

    • Table Active Biotech Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Active Biotech Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Active Biotech Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Millennium Pharmaceuticals Company Details

    • Table Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Table Northwest Biotherapeutics Company Details

    • Table Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Main Business and Markets Served

    • Table Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Product Portfolio

    • Figure Global Hormonal Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Adding An Anti-Androgen Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Stopping An Anti-Androgen Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Estrogens Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Castration Resistant Prostate Cancer Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Castration Resistant Prostate Cancer Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US